The ZMYND8/CEBPE axis leads to a substantial reduction in IRE1α levels, and IRE1α inhibition has been demonstrated to significantly increase the therapeutic efficacy of PIs.[38] These findings provide a biological rationale for combining CFZ with the upregulation of ZMYND8 expression for the treatment of MM. This evidence concerns the gene ZMYND8 and Miyoshi myopathy.